Prediction of Drug-Like Molecular Properties
Prediction of Drug-Like Molecular Properties
复制标题
药物样分子特性的预测
DOI:
10.1385/1-59259-802-1:449
复制
发表时间:
2004
期刊:
影响因子:
--
通讯作者:
C. Waller
中科院分区:
文献类型:
--
作者:
M. Jalaie;R. Arimoto;E. Gifford;S. Schefzick;C. Waller
Preventing drug-drug interactions and reducing drug-related mortalities dictate cleaner and costlier medicines. The cost to bring a new drug to market has increased dramatically over the last 10 years, with post-discovery activities (preclinical and clinical) costs representing the majority of the spend. With the ever-increasing scrutiny that new drug candidates undergo in the post-discovery assessment phases, there is increasing pressure on discovery to deliver higher-quality drug candidates. Given that compound attrition in the early clinical stages can often be attributed to metabolic liabilities, it has been of great interest lately to implement predictive measures of metabolic stability/ liability in the drug design stage of discovery. The solution to this issue is wrapped in understanding the basic of the cytochrome P450 (CYP) enzymes functions and structures. Recently, experimental information on the structure of a variety of cytochrome P450 enzymes, major contributors to phase I metabolism, has become readily available. This, coupled with the availability of experimental information on substrate specificities, has lead to the development of numerous computational models (macromolecular, pharmacophore, and structure-activity) for the rationalization and prediction of CYP liabilities. A comprehensive review of these models is presented in this chapter.
登录
查看更多内容
影响因子:
2.9
作者:
Nelson,DR;Strobel,HW
通讯作者:
Strobel,HW
影响因子:
7.3
作者:
Rao,S;Aoyama,R;Schrag,M;Trager,WF;Rettie,A;Jones,JP
通讯作者:
Jones,JP
影响因子:
2.9
作者:
G. Szklarz;Y. He;J. Halpert
通讯作者:
G. Szklarz;Y. He;J. Halpert
影响因子:
2.9
作者:
Hosea, NA;Miller, GP;Guengerich, FP
通讯作者:
Guengerich, FP
影响因子:
2.9
作者:
Raag,R;Li,H;Jones,BC;Poulos,TL
通讯作者:
Poulos,TL